MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference
January 03 2019 - 8:00AM
MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical
company pioneering precision medicine for the treatment of
cardiovascular diseases, today announced that Tassos Gianakakos,
Chief Executive Officer, will present at the 37th Annual J.P.
Morgan Healthcare Conference on Monday, January 7th, 2019, at 8:30
a.m. PT (11:30 a.m. ET) in San Francisco.
A webcast of the presentation will be available
by visiting the Investors section of MyoKardia’s website
at http://investors.myokardia.com. A replay of the
webcast will be available on the MyoKardia website for 90 days
following the conference.
About MyoKardiaMyoKardia
is a clinical-stage biopharmaceutical company pioneering a
precision medicine approach to discover, develop and commercialize
targeted therapies for the treatment of serious and rare
cardiovascular diseases. MyoKardia’s initial focus is on the
development of small molecule therapeutics aimed at the cardiac
muscle proteins that modulate cardiac muscle contraction and
underlie diseases of systolic and diastolic dysfunction. Based on
an in-depth understanding of disease biology, MyoKardia applies a
precision medicine approach to develop its therapeutic candidates
for patient populations with shared characteristics, such as causal
genetic mutations or disease subtypes. MyoKardia’s most advanced
product candidate is mavacamten (formerly MYK-461), a novel, oral,
allosteric modulator of cardiac myosin intended to reduce
hypercontractility. Mavacamten has advanced into a pivotal Phase 3
clinical trial, known as EXPLORER-HCM in patients with symptomatic,
obstructive hypertrophic cardiomyopathy (HCM). MyoKardia is also
developing mavacamten in a second indication, non-obstructive HCM,
in the Phase 2 MAVERICK-HCM clinical trial. MYK-491, MyoKardia’s
second product candidate, is designed to increase cardiac output
among patients with systolic heart dysfunction by increasing the
overall extent of the heart’s cardiac contractility. MyoKardia is
currently evaluating MYK-491 in a Phase 1b/2a study in stable heart
failure patients.
MyoKardia’s mission is to change the world for
patients with serious cardiovascular disease through bold and
innovative science.
Contacts:
Michelle Corral Corporate Communications & Investor
RelationsMyoKardia, Inc.650-351-4690mcorral@myokardia.comHannah
Deresiewicz (investors)Stern Investor Relations,
Inc.212-362-1200hannahd@sternir.com
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
MyoKardia (NASDAQ:MYOK)
Historical Stock Chart
From Apr 2023 to Apr 2024